[Bone disease in patients undergoing chronic hemodialysis treatment and the role in its development of magnesium in drinking water used in the preparation of dialysis solution].
Studying the role of magnesium on uremic osseous disease in patients on chroniohemodialysis we examined 50 patients with chrovic renal diseases, chronic renal insufficiency (CRI) and chroniodialysis treatment (CDT) with duration of the dialysis treatment from I to 10 years, 3 years on the average, and compared it with control groups of 20 patients with chronic renal diseases without CRI, with duration of the diseases from 3 to 22 years, 9 years on the average and 20 patients with chronic renal diseases and CRI (stage I--III) on conservative treatment, with a duration of the CRI from 0.5 to 6 years, 2 years on the average. The following indices were studied in all patients: serum levels of calcium, phosphorus, magnesium and alkaline phosphatase--montry, to the dialysis patients the samples were taken at the beginning of dialysis séance, and calcium and magnesium content in drinking water used for the preparation of dialysis solution, was twice yearly investigated. In accordance with the bibliographic check up, the bones of all patients adequate for study were photographed with "soft" (mu)-roentgen rays, three times for the observation period, but severe bone changes (osteonecrosis and fractures)--were not established. The level of magnesium in serum of the patients by the end of dialysis séances in the significant group of them was impressive (p less than 0,001).(ABSTRACT TRUNCATED AT 250 WORDS)